Drug-infused nanoparticle is right for sore eyes

The eye drops progressively deliver the right amount of drug-infused nanoparticles to the surface of the eyeball over a period of five days before the body absorbs them.  One weekly dose replaces 15 or more to treat the pain and irritation of dry eyes.

The nanoparticles, about 1/1000th the width of a human hair, stick harmlessly to the eye’s surface and use only five per cent of the drug normally required.

“You can’t tell the difference between these nanoparticle eye drops and water,” said Shengyan (Sandy) Liu, a PhD candidate at Waterloo's Faculty of Engineering, who led the team of researchers from the Department of Chemical Engineering and the Centre for Contact Lens Research. “There’s no irritation to the eye.”

Dry eye syndrome is a more common ailment for people over the age of 50 and may eventually lead to eye damage. More than six per cent of people in the U.S. have it. Currently, patients must frequently apply the medicine three times a day because of the eye’s ability to self-cleanse—a process that washes away 95 per cent of the drug. 

“I knew that if we focused on infusing biocompatible nanoparticles with Cyclosporine A, the drug in the eye drops, and make them stick to the eyeball without irritation for longer periods of time, it would also save patients time and reduce the possibility of toxic exposure due to excessive use of eye drops,” said Liu.

The research team is now focusing on preparing the nanoparticle eye drops for clinical trials with the hope that this nanoparticle therapy could reach the shelves of drugstores within five years.

Liu’s research article, co-authored by eight others including Professors Frank Gu and Lyndon Jones from Waterloo, recently appeared in Nano Research, the leading publication on nanotechnology and nanoscience. The Natural Sciences and Engineering Research Council of Canada (NSERC) and 20/20: Ophthalmic Materials Network supported the research.

About the University of Waterloo

In just half a century, the University of Waterloo, located at the heart of Canada's technology hub, has become one of Canada's leading comprehensive universities with 35,000 full- and part-time students in undergraduate and graduate programs. Waterloo, as home to the world's largest post-secondary co-operative education program, embraces its connections to the world and encourages enterprising partnerships in learning, research and discovery. In the next decade, the university is committed to building a better future for Canada and the world by championing innovation and collaboration to create solutions relevant to the needs of today and tomorrow. For more information about Waterloo, please visit www.uwaterloo.ca.

Media Contact

Pamela Smyth
University of Waterloo
519-888-4777
psmyth@uwaterloo.ca
www.uwaterloo.ca/news
@UWaterlooNews

Attention broadcasters: Waterloo has facilities to provide broadcast quality audio and video feeds with a double-ender studio. Please contact us for more information. 

Media Contact

Pamela Smyth Eurek Alert!

All latest news from the category: Health and Medicine

This subject area encompasses research and studies in the field of human medicine.

Among the wide-ranging list of topics covered here are anesthesiology, anatomy, surgery, human genetics, hygiene and environmental medicine, internal medicine, neurology, pharmacology, physiology, urology and dental medicine.

Back to home

Comments (0)

Write a comment

Newest articles

Urban stormwater detention basin affected by salt pollution and salt-tolerant plants

Going Green: Fighting Freshwater Salt Pollution with Phytoremediation

Salt pollution in freshwater is a growing global concern. Excessive salt harms plants, degrades soil, and compromises water quality. In urban areas, road salts used for de-icing during winter often…

Illustration of leaky gut and inflammation in psoriasis research

Psoriasis Patients at Increased Risk for Crohn’s Due to Gut Inflammation

People with the skin condition psoriasis often have invisible inflammation in the small intestine with an increased propensity for ‘leaky gut’, according to new research at Uppsala University. These changes…

Vials of GLP-1 receptor agonist drugs illustrating benefits and potential risks

Popular Weight-Loss Drugs—Beneficial or Risky?

GLP-1 medications tied to decreased risk of dementia, addiction; increased risk of kidney, pancreas and gastrointestinal problems Growing Public Demand for GLP-1RA Weight-Loss Medications Demand for weight-loss medications sold under…